Series B financing brings total capital raised since 2016 to over US$ 100 million (>RMB 750 million) CHENGDU, China, November 27, 2019-- Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a US$ 43 million (RMB 304 million) Series B financing. This financing round brings Clover’s total capital raised since 2016 to over US$ 100 million (over RMB 750 million). The Series B round was led by Delos Capital and Lapam Capital, with participation from Betta Capital, Sichuan Health Care Industry Fund, Beijing Zhongguancun VC and Jinlong Group.